Fatty liver disease is one of the major causes of morbidity and mortality worldwide. Fatty liver
includes non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as
NAFLD, has ascended to prominence as the predominant chronic liver disease in Western …

Obeticholic acid (OCA) is the second-line therapy for primary biliary cholangitis (PBC), as
well as an attractive candidate as a treatment for metabolic dysfunction-associated …

Non-alcoholic fatty liver disease (NAFLD) is a major public health issue worldwide. It is the
most common liver disease in Western countries, andits global prevalence is estimated to be …

The farnesoid X receptor (FXR) plays a crucial role in regulating the metabolism of bile
acids, lipids, and sugars. Consequently, it is implicated in the treatment of various diseases …

Diet and gut microbiota impact the progression of non-alcoholic steatohepatitis (NASH). An
unhealthy diet, rich in fat and sugar, promotes gut microbiota dysbiosis, leading to the …

Background Nonalcoholic steatohepatitis (NASH), a severe systemic and inflammatory
subtype of nonsalcoholic fatty liver disease, eventually develops into cirrhosis and …

Obeticholic acid (OCA) or 6-alpha-ethyl-chenodeoxycholic acid is a semisynthetic modified
bile acid derivative that acts on the farnesoid X receptor (FXR) as an agonist with a higher …

Introduction Primary sclerosing cholangitis (PSC) is a bile duct disorder characterized by
ductular reaction, hepatic inflammation, and liver fibrosis. The pathogenesis of PSC is still …

Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic disease characterized
by the destruction of the small intrahepatic bile ducts, which can progress to liver cirrhosis …